Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System

Documenti analoghi

• Lichen planus‐like drug eruption: A disproportionality analysis using FAERS database
  di: Tung S. Tran, et al.
  Pubblicazione: (2025)
• Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )
  di: Patrick Jedlowski, et al.
  Pubblicazione: (2025)
• A Case Report of Symmetrical Drug‐Related Intertriginous and Flexural Exanthema‐Like Eruption Associated With Borrelial Infection
  di: Elyana Espinoza, et al.
  Pubblicazione: (2025)
• Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle‐Aged Patients? A Real‐World Disproportionality Analysis of the FDA Adverse Event Reporting System
  di: Chenyang Yu, et al.
  Pubblicazione: (2025)
• Active Switch From a Single Dose of Bimekizumab to Risankizumab in Psoriasis: A Pilot Study
  di: Kaori Nakajima, et al.
  Pubblicazione: (2025)